Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: A novel therapeutic target

Laboratory Investigation

Volumn 95, Issue 12, 2015, Pages 1363-1373

  Asaka, Ryoichi ^a   Miyamoto, Tsutomu ^a   Yamada, Yasushi ^a   Ando, Hirofumi ^a   Mvunta, David Hamisi ^a   Kobara, Hisanori ^a   Shiozawa, Tanri ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL; PROTEIN P53; SELISISTAT; SIRTUIN 1; 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE; CARBAZOLE DERIVATIVE; SIRT1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CALORIE; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DIET; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; MUTATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, ENDOMETRIOID; DRUG RESISTANCE; DRUG SCREENING; ENDOMETRIAL NEOPLASMS; METABOLISM; NUDE MOUSE; PHYSIOLOGICAL STRESS; TUMOR CELL LINE;

ANIMALS; CARBAZOLES; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, INBRED BALB C; MICE, NUDE; SIRTUIN 1; STRESS, PHYSIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84948450289     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.119     Document Type: Article

References (50)

1. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578
2. Goodman MT, Hankin JH, Wilkens LR et al. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res 1997;57: 5077-5085
3. Berstein LM, Tchernobrovkina AE, Gamajunova VB et al. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 2003;129:245-249
4. Hirano S, Ito N, Takahashi S et al. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur J Gynaecol Oncol 2004;25:187-191
5. Petridou E, Mantzoros C, Dessypris N et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab 2003;88:993-997
6. Viswanathan M, Guarente L. Regulation of Caenorhabditis elegans lifespan by sir-2.1 transgenes. Nature 2011;477:E1-E2
7. Weindruch R. The retardation of aging by caloric restriction: studies in rodents and primates. Toxicol Pathol 1996;24:742-745
8. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999;13:2570-2580
9. North BJ, Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol 2004;5:224
10. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for lifespan extension by calorie restriction in Saccharomyces cerevisiae. Science 2000;289:2126-2128
11. Vaziri H, Dessain SK, Ng Eaton E et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-159
12. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer 2010;12:819-823
13. Stnkel W, Peh BK, Tan YC et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2007;2:1360-1368
14. Lee H, Kim KR, Noh SJ et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011;42: 204-213
15. Pecorelli S. Revised FIGO staging for carcinoma of vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-104
16. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol 1975;122:262-263
17. Shiozawa T, Miyamoto T, Kashima H et al. Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene 2004;23:8603-8610
18. Miyamoto T, Kashima H, Suzuki A et al. Laser-captured microdissectionmicroarray analysis of the genes involved in endometrial carcinogenesis: stepwise up-regulation of lipocalin2 expression in normal and neoplastic endometria and its functional relevance. Hum Pathol 2011;42:1265-1274
19. Napper AD, Hixon J, McDonagh T et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005;48: 8045-8054
20. Luo J, Nikolaev AY, Imai S et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001;107:137-148
21. Risinger JI, Dent GA, Ignar-Trowbridge D et al. p53 gene mutations in human endometrial carcinoma. Mol Carcinog 1992;5:250-253
22. Feng YZ, Shiozawa T, Horiuchi A et al. Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas. Virchows Arch 2005;447:816-822
23. Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer 1966;19:489-520
24. Brachmann CB, Sherman JM, Devine SE et al. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev 1995;9: 2888-2902
25. Shiozawa T, Li SF, Nakayama K et al. Relationship between the expression of cyclins/cyclin-dependent kinases and sex-steroid receptors/ Ki67 in normal human endometrial glands and stroma during the menstrual cycle. Mol Hum Reprod 1996;2:745-752
26. Elangovan S, Ramachandran S, Venkatesan N et al. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. Cancer Res 2011;71:6654-6664
27. Wu M, Wei W, Xiao X et al. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triplenegative and non-triple-negative breast cancer. Med Oncol 2012;29: 3240-3249
28. Noh SJ, Baek HA, Park HS et al. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer. Pathol Res Pract 2013;209:365-370
29. Stenzinger A, Endris V, Klauschen F et al. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer 2013;13:450
30. Kriegl L, Vieth M, Kirchner T et al. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget 2012;3:1182-1193
31. Huffman DM, Grizzle WE, Bamman MM et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007;67: 6612-6618
32. Ikenoue T, Inoki K, Zhao B et al. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res 2008;68:6908-6912
33. Sundaresan NR, Pillai VB, Wolfgeher D et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 2011;4:ra46
34. Wang Z, Chen W. Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes Cancer 2013;4:82-90
35. Kim EJ, Kho JH, Kang MR et al. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 2007;28: 277-290
36. Li M, Luo J, Brooks CL et al. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002;277:50607-50611
37. Choi HK, Cho KB, Phuong NT et al. SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells. Mol Pharm 2013;10: 2517-2527
38. Goto T, Takano M, Albergaria A et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 2008;27:9-19
39. Wang F, Chan C-H, Chen K et al. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene 2012;31:1546-1557
40. Ueno T, Endo S, Saito R et al. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-Fluorouracil and oxaliplatin in colon cancer cells. Oncol Res 2014;21:155-164
41. Kabra N, Li Z, Chen L et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009;284:18210-18217
42. Peck B, Chen CY, Ho KK et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 2010;9:844-855
43. Zhang JG, Hong DF, Zhang CW et al. Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress. Cancer Sci 2014;105:445-454
44. Oon CE, Strell C, Yeong KY et al. SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo. Eur J Pharmacol 2015;757:59-67
45. Yang Y, Jiang S, Dong Y et al. Melatonin prevents cell death and mitochondrial dysfunction via a SIRT1-dependent mechanism during ischemic-stroke in mice. J Pineal Res 2015;58:61-70
46. Gong DJ, Zhang JM, Yu M et al. Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma. Clin Interv Aging 2013;8:889-897
47. Laemmle A, Lechleiter A, Roh V et al. Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1α protein under hypoxic conditions. PLoS One 2012;7:e33433
48. Suchankova G, Nelson LE, Gerhart-Hines Z et al. Concurrent regulation of AMP-activated protein kinase and SIRT1 in mammalian cells. Biochem Biophys Res Commun 2009;378:836-841
49. Milne JC, Lambert PD, Schenk S et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:712-716
50. Ma W, Xiao GG, Mao J et al. Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness. Oncotarget 2015;6:10432-10444